BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1200 related articles for article (PubMed ID: 31209815)

  • 1. Flexible GnRH Antagonist Protocol versus Progestin-primed Ovarian Stimulation (PPOS) Protocol in Patients with Polycystic Ovary Syndrome: Comparison of Clinical Outcomes and Ovarian Response.
    Xiao ZN; Peng JL; Yang J; Xu WM
    Curr Med Sci; 2019 Jun; 39(3):431-436. PubMed ID: 31209815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
    Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progestin-primed ovarian stimulation is a feasible method for poor ovarian responders undergoing in IVF/ICSI compared to a GnRH antagonist protocol: A retrospective study.
    Huang P; Tang M; Qin A
    J Gynecol Obstet Hum Reprod; 2019 Feb; 48(2):99-102. PubMed ID: 30321608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progestin primed ovarian stimulation using corifollitropin alfa in PCOS women effectively prevents LH surge and reduces injection burden compared to GnRH antagonist protocol.
    Huang TC; Huang MZ; Seow KM; Yang IJ; Pan SP; Chen MJ; Hwang JL; Chen SU
    Sci Rep; 2021 Nov; 11(1):22732. PubMed ID: 34815477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles.
    Yu S; Long H; Chang HY; Liu Y; Gao H; Zhu J; Quan X; Lyu Q; Kuang Y; Ai A
    Hum Reprod; 2018 Feb; 33(2):229-237. PubMed ID: 29300975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of progestin-primed ovarian stimulation in women with polycystic ovary syndrome undergoing
    Yang L; Liang F; Yuan Y; Luo X; Wang Q; Yao L; Zhang X
    Front Endocrinol (Lausanne); 2023; 14():1224858. PubMed ID: 37795363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of a progestin-primed ovarian stimulation protocol with a flexible GnRH antagonist protocol in patients with polycystic ovary syndrome who are participating in an IVF programme: study protocol for a randomised controlled trial.
    Wang N; Zhu Q; Ma M; Liang Z; Tao Y; Wang Y; Kuang Y
    BMJ Open; 2020 Dec; 10(12):e038153. PubMed ID: 33268401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of Different Gonadotropin-releasing Hormone Agonist Administration Methods on Pregnancy Outcomes of Patients Undergoing In-vitro Fertilization-embryo Transfer.
    Wu L; Ren XL; Chen W; Huang B; Zhou YF; Jin L
    Curr Med Sci; 2019 Jun; 39(3):437-441. PubMed ID: 31209816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controlled Ovarian Stimulation Using Medroxyprogesterone Acetate and hMG in Patients With Polycystic Ovary Syndrome Treated for IVF: A Double-Blind Randomized Crossover Clinical Trial.
    Wang Y; Chen Q; Wang N; Chen H; Lyu Q; Kuang Y
    Medicine (Baltimore); 2016 Mar; 95(9):e2939. PubMed ID: 26945402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progestin-primed milder stimulation with clomiphene citrate yields fewer oocytes and suboptimal pregnancy outcomes compared with the standard progestin-primed ovarian stimulation in infertile women with polycystic ovarian syndrome.
    Ye H; Tian H; He W; Lyu Q; Kuang Y; Chen Q; Sun L
    Reprod Biol Endocrinol; 2018 May; 16(1):53. PubMed ID: 29807533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-vitro maturation of oocytes vs in-vitro fertilization with a gonadotropin-releasing hormone antagonist for women with polycystic ovarian syndrome: can superiority be defined?
    Shavit T; Ellenbogen A; Michaeli M; Kartchovsky E; Ruzov O; Shalom-Paz E
    Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():46-50. PubMed ID: 24965979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual suppression with oral contraceptive pills in GnRH antagonist cycles for patients with polycystic ovary syndrome undergoing intracytoplasmic sperm injection.
    Ozmen B; Sükür YE; Seval MM; Ateş C; Atabekoğlu CS; Sönmezer M; Berker B
    Eur J Obstet Gynecol Reprod Biol; 2014 Dec; 183():137-40. PubMed ID: 25461367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial.
    Prapas Y; Ravanos K; Petousis S; Panagiotidis Y; Papatheodorou A; Margioula-Siarkou C; Iuliano A; Gullo G; Prapas N
    J Assist Reprod Genet; 2017 Nov; 34(11):1537-1545. PubMed ID: 28776117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vitro maturation versus IVF with GnRH antagonist for women with polycystic ovary syndrome: treatment outcome and rates of ovarian hyperstimulation syndrome.
    Das M; Son WY; Buckett W; Tulandi T; Holzer H
    Reprod Biomed Online; 2014 Nov; 29(5):545-51. PubMed ID: 25262236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian response and embryo ploidy following oral micronized progesterone-primed ovarian stimulation versus GnRH antagonist protocol. A prospective study with repeated ovarian stimulation cycles.
    Vidal MDM; Martínez F; Rodríguez I; Polyzos NP
    Hum Reprod; 2024 May; 39(5):1098-1104. PubMed ID: 38498835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pregnancy outcome of progestin-primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: a randomised controlled trial.
    Dong J; Wang Y; Chai WR; Hong QQ; Wang NL; Sun LH; Long H; Wang L; Tian H; Lyu QF; Lu XF; Chen QJ; Kuang YP
    BJOG; 2017 Jun; 124(7):1048-1055. PubMed ID: 28276192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the Cumulative Live Birth Rates of Progestin-Primed Ovarian Stimulation and Flexible GnRH Antagonist Protocols in Patients With Low Prognosis.
    Du M; Zhang J; Li Z; Liu X; Li J; Liu W; Guan Y
    Front Endocrinol (Lausanne); 2021; 12():705264. PubMed ID: 34589055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison the effects of progestin-primed ovarian stimulation (PPOS) protocol and GnRH-a long protocol in patients with normal ovarian reserve function.
    Xu S; Wang X; Zhang Y; Han Y; Zhang C
    Gynecol Endocrinol; 2023 Dec; 39(1):2217263. PubMed ID: 37236243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conventional GnRH antagonist protocols versus long GnRH agonist protocol in IVF/ICSI cycles of polycystic ovary syndrome women: a systematic review and meta-analysis.
    Kadoura S; Alhalabi M; Nattouf AH
    Sci Rep; 2022 Mar; 12(1):4456. PubMed ID: 35292717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of GnRH antagonist fixed protocol and GnRH agonists long protocol in infertile patients with normal ovarian reserve function in their first in vitro fertilization-embryo transfer cycle].
    Yang S; Chen XN; Qiao J; Liu P; Li R; Chen GA; Ma CH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):245-9. PubMed ID: 22781108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 60.